New Meridian Bioscience, Inc. (VIVO) Patent Improves Rubella Testing Accuracy
10/19/2005 5:09:19 PM
CINCINNATI--(BUSINESS WIRE)--June 22, 2005--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that Viral Antigens, Inc. (VAI), a wholly owned life science subsidiary, received a patent entitled "Specificity in the Detection of Anti-Rubella IgM Antibodies" from the U.S. Patent and Trademark Office. This patent encompasses improved methods for detection of anti-rubella IgM antibodies in commercial diagnostic products, utilized to test blood samples for the presence of rubella antibodies. VAI is a leading supplier of purified virus proteins that are used by clinical diagnostic test manufacturers. The allowance of this patent (Patent No. 6,872,396) further strengthens VAI's intellectual property position and adds further claims to the first patent issued on December 30, 2003.